Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)

被引：0

作者：

Yau, T. ^{[1
]}

Cheng, A-L. ^{[2
]}

Meyer, T. ^{[3
]}

Ryoo, B-Y. ^{[4
]}

Park, J-W. ^{[5
]}

Klumpen, H-J. ^{[6
]}

Lim, H. Y. ^{[7
]}

Kim, S. ^{[8
]}

Knox, J. ^{[9
]}

Patel, M. ^{[10
]}

El-Khoueiry, A. B. ^{[11
]}

Kelley, R. K. ^{[12
]}

Abou-Alfa, G. K. ^{[13
]}

机构：

[1] Queen Mary Hosp, Oncol, Hong Kong, Peoples R China

[2] Natl Taiwan Univ Hosp, Taipei, Taiwan

[3] Royal Free Hosp, Med Oncol, London, England

[4] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[5] Natl Canc Ctr, Ctr Liver Canc, Goyang Si, South Korea

[6] Acad Med Ctr, Dept Med Oncol, Amsterdam, Netherlands

[7] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[8] CHU Besancon, Besancon, France

[9] Princess Margaret Hosp, Toronto, ON, Canada

[10] Exelixis Inc, San Francisco, CA USA

[11] USC Norris Comprehens Canc Ctr, Med Oncol, Los Angeles, CA USA

[12] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Div Hematol Oncol, San Francisco, CA 94143 USA

[13] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

704P

引用

页数：2